全文获取类型
收费全文 | 102975篇 |
免费 | 45802篇 |
国内免费 | 152篇 |
专业分类
耳鼻咽喉 | 1813篇 |
儿科学 | 4873篇 |
妇产科学 | 1056篇 |
基础医学 | 20783篇 |
口腔科学 | 5743篇 |
临床医学 | 14699篇 |
内科学 | 28411篇 |
皮肤病学 | 8147篇 |
神经病学 | 16222篇 |
特种医学 | 3554篇 |
外科学 | 18176篇 |
综合类 | 159篇 |
一般理论 | 36篇 |
预防医学 | 5617篇 |
眼科学 | 1914篇 |
药学 | 7653篇 |
中国医学 | 1016篇 |
肿瘤学 | 9057篇 |
出版年
2021年 | 1539篇 |
2020年 | 5271篇 |
2019年 | 11154篇 |
2018年 | 10524篇 |
2017年 | 11741篇 |
2016年 | 12522篇 |
2015年 | 12400篇 |
2014年 | 12423篇 |
2013年 | 13244篇 |
2012年 | 5558篇 |
2011年 | 5647篇 |
2010年 | 9886篇 |
2009年 | 6235篇 |
2008年 | 3835篇 |
2007年 | 2729篇 |
2006年 | 2615篇 |
2005年 | 2560篇 |
2004年 | 2430篇 |
2003年 | 2377篇 |
2002年 | 2404篇 |
2001年 | 843篇 |
2000年 | 593篇 |
1999年 | 405篇 |
1998年 | 447篇 |
1997年 | 372篇 |
1996年 | 318篇 |
1995年 | 354篇 |
1994年 | 308篇 |
1993年 | 271篇 |
1992年 | 227篇 |
1991年 | 214篇 |
1990年 | 174篇 |
1989年 | 170篇 |
1988年 | 175篇 |
1987年 | 143篇 |
1985年 | 162篇 |
1984年 | 185篇 |
1983年 | 164篇 |
1982年 | 201篇 |
1981年 | 174篇 |
1978年 | 140篇 |
1933年 | 170篇 |
1932年 | 180篇 |
1931年 | 167篇 |
1930年 | 169篇 |
1929年 | 147篇 |
1928年 | 163篇 |
1927年 | 144篇 |
1926年 | 158篇 |
1925年 | 139篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
1.
2.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
3.
European Journal of Epidemiology - Existing research has found adverse short-term effects of the COVID-19 pandemic on mental health, but longer-term effects have been less documented. Using newly... 相似文献
4.
5.
Darren Ming‐Chun Poon 《Asia-Pacific Journal of Clinical Oncology》2020,16(Z3):18-23
For advanced and metastatic urothelial carcinomas (UCs), platinum (preferably cisplatin)‐based chemotherapy has been the standard treatment for many years. However, many patients are ineligible for cisplatin‐based chemotherapy because of poor performance status and/or other age‐related conditions. At the other end of the spectrum, patients with localized non‐muscle–invasive bladder cancer who are unresponsive to intravesical Bacillus Calmette‐Guérin (BCG) treatment often face radical cystectomy as the only option. In recent years, the application of immunotherapy in the form of immune‐checkpoint inhibitors has provided viable alternatives in the second‐line postplatinum and first‐line cisplatin‐ineligible settings. Recent and ongoing clinical trials are also assessing the safety and efficacy of immunotherapy for neoadjuvant and adjuvant uses before/after cystectomy, for BCG‐unresponsive cases, and for combination treatments that include the newer indoleamine 2,3‐dioxygenase‐1 inhibitors and/or BCG. This review summarizes recent developments in immunotherapy for UCs. 相似文献
6.
7.
8.
9.
Javad Sharifi‐Rad Shahira M. Ezzat Mahitab H. El Bishbishy Dima Mnayer Farukh Sharopov Ceyda S. Kl Monica Neagu Carolina Constantin Mehdi Sharifi‐Rad Maria Atanassova Silvana Nicola Giuseppe Pignata Bahare Salehi Patrick V. T. Fokou Natlia Martins 《Phytotherapy research : PTR》2020,34(7):1474-1518
Rosmarinus species are aromatic plants that mainly grow in the Mediterranean region. They are widely used in folk medicine, food, and flavor industries and represent a valuable source of biologically active compounds (e.g., terpenoids, flavonoids, and phenolic acids). The extraction of rosemary essential oil is being done using three main methods: carbon dioxide supercritical extraction, steam distillation, and hydrodistillation. Furthermore, interesting antioxidant, antibacterial, antifungal, antileishmanial, anthelmintic, anticancer, anti‐inflammatory, antidepressant, and antiamnesic effects have also been broadly recognized for rosemary plant extracts. Thus the present review summarized data on economically important Rosmarinus officinalis species, including isolation, extraction techniques, chemical composition, pharmaceutical, and food applications. 相似文献